Saw Palmetto for GLP-1 Hair Loss: The Androgenetic Angle (2026)

The mechanism of saw palmetto in androgenetic alopecia centres on 5-alpha-reductase (5AR) inhibition. The liposterolic fatty acid compounds in Serenoa repens extract — particularly the free fatty acids lauric acid, oleic acid, and myristic acid — inhibit both type 1 and type 2 isoforms of 5AR. This enzyme catalyses the conversion of testosterone to dihydrotestosterone (DHT), which is approximately 3–5 times more potent than testosterone at the androgen receptor. In follicles with genetic sensitivity to DHT (those expressing androgen receptors at the dermal papilla), sustained DHT signalling drives progressive miniaturisation — shorter hair growth cycles, progressively thinner shafts, and eventual follicle dormancy. By reducing 5AR activity, saw palmetto lowers DHT conversion in tissues where the extract is distributed. The degree of DHT reduction with Serenoa repens extract is substantially less than with pharmaceutical finasteride (which produces ~70% DHT reduction vs. ~32% for saw palmetto in the best-studied trials) — which accounts for saw palmetto's lower overall efficacy but also explains its much better safety profile. The GLP-1 context for this mechanism is as follows: adipose tissue expresses aromatase (CYP19A1), which converts androgens (androstenedione, testosterone) into oestrogens. In individuals with significant excess body fat, substantial androgen aromatisation occurs in fat tissue, effectively buffering circulating free testosterone. As GLP-1 medication users lose fat mass rapidly — sometimes 15–25% of body weight in the first 6–12 months — this aromatase buffer shrinks. Less androgen is aromatised to oestrogen, leaving more free testosterone available for 5AR conversion to DHT in scalp follicles. In individuals with genetic sensitivity, this DHT exposure can accelerate or unmask the miniaturisation pattern characteristic of AGA. Saw palmetto does not change the hormonal shift from fat loss — but it may blunt the downstream DHT conversion that drives follicle miniaturisation. Recent mechanistic research (Broadley et al., PMID 41126502) has also identified that Serenoa repens liposterolic extract promotes hair growth through additional pathways including Wnt/β-catenin signalling activation (a key pathway for follicle stem cell maintenance) and anti-inflammatory effects in the follicle microenvironment — suggesting the mechanism is broader than simple 5AR inhibition alone.

Saw palmetto buying decisions come down primarily to extract type and commitment to a sufficient duration of use. **Extract type is non-negotiable: liposterolic extract standardised to 85–95% fatty acids only.** The clinical research on saw palmetto and hair loss has used liposterolic extract standardised to this fatty acid concentration. Berry powder products, non-standardised extracts, and dry herb capsules are not equivalent and lack the evidence base. Check the label carefully: it should specify the extract is standardised to 85–95% fatty acids, not simply 'saw palmetto berry' or 'whole berry powder.' All three products in this review use the correct extract type. **Dose: 160–320mg daily.** The dose range used in AGA trials is typically 160–320mg of standardised liposterolic extract per day, taken as either a single dose or split dose. Some protocols use the full 320mg as a single daily dose; others use 160mg twice daily. The evidence doesn't clearly differentiate between these approaches. Starting at 160mg daily and assessing tolerability over the first 4–6 weeks is reasonable. **Duration: commit to at least 6 months before assessing results.** The AGA trials that showed meaningful outcomes ran for 6 months or longer. Hair growth cycles operate on 3–6 month timescales, and androgenetic hair loss responds to DHT modulation slowly. Evaluating at 8–12 weeks is too early; a fair trial is 6 months of consistent use. **Saw palmetto vs. finasteride: honest comparison.** Saw palmetto inhibits 5AR more gently than finasteride — producing roughly 32% DHT reduction versus finasteride's ~70%. This means saw palmetto is less powerful, but it is also much less likely to cause the sexual side effects (libido changes, erectile dysfunction) that are documented with finasteride use and have been reported in some cases to persist after discontinuation (post-finasteride syndrome). For GLP-1 users who want to address the androgenetic mechanism without pharmaceutical risk, saw palmetto is a reasonable evidence-informed approach — while being transparent that it is less potent.